The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.
Pharmaceutical distributor CanaRx Services has hit back at criticism from the US Food and Drug Administration over the Canadian company’s alleged supply of unapproved and misbranded drugs.
King’s College London has entered a licensing and collaboration agreement with US pharmaceutical company Merck & Co to develop new chronic pain medications.
The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
The US International Trade Commission has instituted an investigation into certain blood separation and cell preparation devices.
Activist group No Patents on Seeds has filed an opposition against a patent on lettuce, owned by Dutch food supplier Rijk Zwaan Zaadteelt.
The US Court of Appeals for the Federal Circuit yesterday, March 6, refused to rehear a decision which found Allergan and the Saint Regis Mohawk Tribe’s patents for dry-eye treatment Restasis (cyclosporine ophthalmic emulsion) are invalid.
The EU General Court today, March 6, rejected an appeal against an European Union Intellectual Property Office decision to reject the registration of a mark formerly owned by Allergan.
Scott Gottlieb, commissioner of the US Food and Drug Administration, resigned from his post yesterday, March 5, with plans to step down in the next month.
The Information Technology and Innovation Foundation think tank has called on the US National Institutions of Health to maintain IP protection amid calls to “break” patents in order to lower drug prices.